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Subconjunctival hemorrhage (SCH) is a common eye disorder that is characterized by the sudden onset of
a ﬂat area of bleeding under the conjunctiva. Although SCH is a well-known and relatively common
disease, the cause in a number of cases remains unknown. Here, we report an unusual ocular presen-
tation of bulbar SCH in a patient who had received an inﬂuenza vaccine. Patients who present with SCH
other than trauma episode should be evaluated with metabolic diseases or coagulopathy. Although there
are rare cases of SCH related to vaccination, we should closely follow a patient if there is a risk of the SCH
becoming bleeding disorder. To our knowledge, the features of SCH related to vaccination have not been
reported.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Subconjunctival hemorrhage (SCH) is a common eye disorder
that is characterized by the sudden onset of a bleeding area under
the conjunctiva. Although SCH is a well-known and relatively
common disease, the cause in a number of cases remains unknown.
Here, we report an unusual ocular presentation of bulbar SCH in
a patient who had received an inﬂuenza vaccine.
2. Case presentation
A previously ﬁt and active 41-year-old male teacher came into
our emergency department after a routine inﬂuenza vaccination.
The symptoms occurred about 4 hours after he had received an
inﬂuenza vaccination (AdimFlu-S, Adimmune corporation, Taichung,
Taiwan). The patient reported the sudden appearance of redness in
both eyes (Fig. 1) and the appearance of a skin rash over the lower
face to the anterior chest (Fig. 2). The vaccine contained an A/Cal-
ifornia/7/2009 (H1N1) virus-like strain and A/California/7/2009
(H1N1) viral strains(Reassortant NYMC X-179A), which had been
recommended for the 2009 (H1N1) inﬂuenza A pandemic. The
patient had previously been healthy, without a history of recent
infections or drug or egg allergies. Moreover, he had had noology, Taipei City Hospital,
a’an District, Taipei City 106,
e Ophthalmologic Society of Taiwaspontaneous or refractory bleeding episodes in the past, and his
family history was negative for such complaints.
Laboratory investigation revealed no anemia, thrombocytopenia,
leukocytosis or lymphocytosis. The bleeding time, prothrombin
time, activated partial thromboplastin time and the D-dimer
assay were normal. With the exception of a mildly elevated ferritin
level (405 ng/ml; normal: 28e365 ng/ml), the immune-factor tests
for antineutrophil cytoplasmic antibodies, antinuclear antibody,
complement 3, complement 4, antistreptolysin O titer and immu-
noglobulin E level were all within normal range. The Pharmacia CAP
test showed a negative allergic reaction to egg white.
On ocular examination, the best-corrected visual acuity was
bilateral 20/20, and the intraocular pressure was 13/13 mmHg. A
slit-lamp biomicroscopic examination revealed bilateral palpebral
SCH and no signs of intraocular hemorrhage. A fundus image did
not reveal any signs of bleeding.
Intravenous diphenhydramine hydrogen chloride was admin-
istered for a suspected anaphylaxis skin reaction to the vaccination.
The hemorrhage was managed conservatively. The rash subsided
after 3 days of medication and the hemorrhage had resolved at
2-weeks follow-up.
3. Discussion
After the ﬁrst outbreak of H1N1 inﬂuenza A virus infection was
reported in Mexico in 2009, the World Health Organization
announced a worldwide pandemic of the novel inﬂuenza A H1N1
virus and recommended a pandemic action plan for each country.n. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Bilateral bulbar subconjunctival hemorrhage, which is ﬂat, diffuse and upper-sparing distribution: (A) right eye; and (B) left eye.
Fig. 2. Anaphylactic skin manifestation over the lower face to anterior chest.
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a different country, the Taiwanese government initiated the
production of a monovalent split-virus pandemic inﬂuenza A H1N1
vaccine (AdimFlu-S) in Taiwan.1 In these clinical vaccine trials, the
most commonly reported local adverse event was injection-site
pain (24.4%). Redness of the eye was only reported in the ﬁrst
vaccination trial in Taiwan where 4.4% of the 183 participants were
effected.2e4
Mimura et al recently performed a study on risk factors for SCH;
this study involved a large series of consecutive patients. SCH was
most commonly observed to be caused by local trauma or contact-
lens-induced injury in the younger group and by hypertension in
the older group.5 The causative factor remained unknown,
however, for more than 40% of patients with SCH.
To the best of our knowledge, this is the ﬁrst reported case of
bulbar SCH after vaccination. Our patient did not have any bleeding
disorder, medication history or chronic disease. He also denied
squeezing, cough, contact-lens wearing, trauma history, stress or
any increased venous pressure situation before red eye occurred.
Other precipitating causes were excluded in the case of our patient.
Systemic screening during hospitalization did not reveal any
abnormal ﬁnding. The lesions appeared soon after vaccination, sothey may have been caused by a bleeding disorder or an anaphy-
lactic reaction to the vaccine.
Although SCHs are rarely caused by hematological factors, they
may result from subclinical disseminated intravascular coagulation
(DIC). For subclinical DIC, however, clinical evidence of bleeding is
nonspeciﬁc and the laboratory screening tests usually yield normal
results.6 There are isolated reports linking inﬂuenza vaccines with
thrombocytopenia.7e9 The antibodies responsible for the clearance
of viral antigen are naturally present on platelets.
Patients who present with SCH that has not been caused by
trauma should be evaluated for metabolic diseases or coagulopathy.
In most patient series, subclinical or ﬂorid DIC was the most
commonly observed hematological abnormality. Our patient may
have had the SCH because of an anaphylactic reaction related to
subclinical DIC, but the SCH did not develop into a severe bleeding
disorder, presumably as a result of early treatment.
This is the ﬁrst report of SCH that developed associating with
vaccination. Therefore, clinicians should be aware that inﬂuenza
vaccination may be associated with ocular disorders.References
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